Delving into the Latest Updates on Inflachromene with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

Mechanism

HMGB1 inhibitors(High Mobility Group Protein B1 inhibitors), HMGB2 inhibitors(high mobility group box 2 inhibitors), KEAP1 inhibitors(Kelch like ECH associated protein 1 inhibitors)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic Disease

Active Indication

Parkinson DiseaseEpilepsyNeuroinflammation

Inactive Indication-

Originator Organization

Seoul National University

Active Organization

Zhejiang University

Seoul National University

Sparkbiopharma Co., Ltd.

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

ObjectiveTo investigate the incidence of severe iodinated contrast media (ICM)–related hypersensitivity reaction (HSR) and to find the optimal alternative ICM to reduce the risk of severe HSR recurrence.MethodsWe retrospectively reviewed 23,383,183 cases of ICM administration between January 2015 and December 2019 from the nationwide health insurance database. We classified ICMs based on generic profiles and the presence of N-(2,3-dihydroxypropyl) carbamoyl side chains. The incidence of severe and recurrent severe HSRs was calculated, and χ2 tests were performed to compare the prevalence of severe HSR according to ICM groups. In addition, logistic regression analyses were used to assess differences between ICM groups.ResultsThe incidence of severe HSRs was 1.92% (450,067 of 23,282,183). Among 1,875,245 individuals who received ICM twice on different days, severe HSR occurred in 40,850 individuals, and severe HSR recurred in 3319 individuals (8.12%). The risk of recurrence significantly decreased when the ICM changed (9.24% vs 7.08%, P < 0.001), especially when the ICM changed to one with a different side chain (6.74%, P < 0.001). In addition, compared with the reuse of the culprit agent, using combinations of iobitridol/iohexol (odds ratio [OR], 0.696; P = 0.04), iohexol/iopamidol (OR, 0.757; P = 0.007), iopamidol/iohexol (OR, 0.447; P < 0.001), and ioversol/iohexol (OR, 0.683; P = 0.04) reduced the risk of recurrence of severe HSR.ConclusionsChanging the culprit ICM to that with a different side chain can reduce severe HSR recurrence. The optimal choice of an alternative ICM depends on the causative agent.

100 Deals associated with Inflachromene

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Parkinson Disease	Preclinical	KR	Seoul National University	01 Jan 2024
Parkinson Disease	Preclinical	KR	Sparkbiopharma Co., Ltd.	01 Jan 2024
Epilepsy	Preclinical	CN	Zhejiang University	19 Apr 2023
Epilepsy	Preclinical	KR	Seoul National University	19 Apr 2023
Neuroinflammation	Preclinical	KR	Seoul National University	12 Oct 2014